Entrada Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Entrada Therapeutics Inc's ROI in the third quarter of 2026?
Entrada Therapeutics Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -1.75%.

Within the Healthcare sector 102 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 549 to 943.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	-33 %	-28.49 %	-23.15 %	-9.15 %	8.93 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	241	278	316	353	389
Return On Investment (TTM)	-1.75 %	10.15 %	9.07 %	-0.23 %	-15.1 %
TRDA's Overall Ranking	# 943	# 549	# 1928	# 2848	#
Seq. Investment Change TTM	-11.07 %	-10.19 %	-9.26 %	-7.55 %	-5.09 %
Seq. Net Income Change TTM	-	0.42 %	-	-	-
Net Income (TTM) in Millions	-5	34	34	-1	-67

TRDA Company Profile >> Back to TRDA Roi Comparisons >> See Annual TRDA Return On Investment

Return On Investment TRDA's Ranking
Within:	No.
Industry	# 40
Sector	# 103
Overall	# 943

Return On Investment Statistics
High	Average	Low
154.28 %	10.29 %	-46.09 %
(Dec 31 2021)		(Sep 30 2021)

Financial Statements
Entrada Therapeutics Inc's III. Quarter Investments	$ 241 Millions	TRDA's Balance sheet
Entrada Therapeutics Inc's III. Quarter Income	$ -40 Millions	Quarterly TRDA's Income Statement
TRDA's Income by Division		See TRDA's Income by Division

TRDA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	353	487	310	230	299
Y / Y Investment Growth	-27.51 %	56.84 %	34.91 %	-23.08 %	-
Net Income in Millions	-1	132	5	-95	-51
Y / Y Net Income Growth	-	2359.71 %	-	-	-
Annual Return On Investment	-0.26 %	27.14 %	1.73 %	-41.12 %	-17.1 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TRDA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TRDA's Competitors
Subscribers only: Roi for Entrada Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TRDA's Customers

Other Ratios
TRDA's Roa	TRDA's Inventory Turnover Ratio	TRDA's Growth Rates	TRDA's Dividend Statistics
	TRDA's Profitability Ratios	TRDA's Asset Turnover Ratio	TRDA's Dividend Growth
TRDA's Roe	TRDA's Valuation Ratios	TRDA's Financial Strength Ratios	TRDA's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector

ROI

Date modified: 2026-11-06T06:01:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.